Delivered in partnership by Brandon BioCatalyst and ANDHealth, CUREator+ supports the translation and commercial development of promising biomedical and digital health technologies.

Up to $5M non-dilutive funding is available to support breakthrough technologies to drive clinical and commercial impact through preventing, monitoring, managing, diagnosis or treatment of a disease state, its symptoms or risk factors, across three modalities:
– Medical and connected device technologies.
– Digital health technologies.
– Therapeutics.
‍

Successful applicants will also receive:
– Commercial capability-building coaching.
– Hands-on support from the ANDHealth and Brandon BioCatalyst teams.
– Access to a global network of experts.
– Connections to pharmaceutical companies, venture capital firms and institutional investors.
‍

Join us at our upcoming information session to learn all about the program, expression of interest process and selection criteria.

CUREator+ Information Session
Time: 12:00 pm – 1:00 pm (AEDT)
Date: Monday 28 October 2024
Location: Online via Zoom

‍

The expression of interest period closes on 4 December 2024 at 12:00pm (AEDT).
‍

CUREator+ is delivered in partnership with Brandon BioCatalyst and supported by funding from the Medical Research Future Fund (MRFF) BioMedTech Incubator (BMTI) program.

Learn more
Register for information session